# Sunesis Pharmaceuticals, Inc. (SNSS) Source: https://www.quantisnow.com/company/SNSS Generated: 2026-11-09T23:24:37.274Z - Ticker: SNSS - Exchange: NASDAQ - Sector: Health Care - Industry: Major Pharmaceuticals - IPO year: 2005 ## Latest SNSS news and filings - 2021-03-11 02:40 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-498245) - 2021-03-08 22:05 UTC [SEC Schedule 13G] [SEC Form SC 13G filed](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-485224) - 2021-03-05 18:30 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-478228) - 2021-03-04 22:46 UTC [SEC Form 3] [SEC Form 3 filed by J. Barry Simon](https://www.quantisnow.com/insight/sec-form-3-filed-by-j-barry-simon-475579) - 2021-03-04 22:42 UTC [SEC Form 3] [SEC Form 3 filed by Stephen Rubino](https://www.quantisnow.com/insight/sec-form-3-filed-by-stephen-rubino-475563) - 2021-03-04 21:06 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-474436) - 2021-03-02 11:14 UTC [SEC Schedule 13D] [SEC Form SC 13D filed](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-456392) - 2021-03-01 13:39 UTC [Analyst Upgrade] [Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target](https://www.quantisnow.com/insight/sunesis-pharmaceuticals-upgraded-by-oppenheimer-with-a-new-price-target-450942) - 2021-02-25 23:09 UTC [SEC Form 3] [SEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock](https://www.quantisnow.com/insight/sec-form-3-partnership-limited-fund-2-amoon-claimed-ownership-443160) - 2021-02-25 23:03 UTC [SEC Form 3] [SEC Form 3: Gur Roshwalb claimed ownership of 7,392,237 units of Common Stock](https://www.quantisnow.com/insight/sec-form-3-gur-roshwalb-claimed-ownership-of-7392237-units-443146) - 2021-02-25 01:10 UTC [SEC Form 3] [SEC Form 3: R. Daniel Chevallard claimed ownership of 44,760 units of Common Stock](https://www.quantisnow.com/insight/sec-form-3-r-daniel-chevallard-claimed-ownership-of-44760-430518) - 2021-02-25 01:02 UTC [SEC Form 3] [SEC Form 3 filed by E Thomas Darcy](https://www.quantisnow.com/insight/sec-form-3-filed-by-e-thomas-darcy-430505) - 2021-02-25 00:54 UTC [SEC Form 3] [SEC Form 3 filed by Michael Huang](https://www.quantisnow.com/insight/sec-form-3-filed-by-michael-huang-430486) - 2021-02-25 00:49 UTC [SEC Form 3] [SEC Form 3 filed by Lafayette Samuel Murphy](https://www.quantisnow.com/insight/sec-form-3-filed-by-lafayette-samuel-murphy-430479) - 2021-02-25 00:45 UTC [SEC Form 3] [SEC Form 3 filed by Roger Pomerantz](https://www.quantisnow.com/insight/sec-form-3-filed-by-roger-pomerantz-430473) - 2021-02-25 00:40 UTC [SEC Form 3] [SEC Form 3 filed by Lisa Rojkjaer](https://www.quantisnow.com/insight/sec-form-3-filed-by-lisa-rojkjaer-430466) - 2021-02-25 00:31 UTC [SEC Form 3] [SEC Form 3: Ivor Royston claimed ownership of 559,198 units of Common Stock](https://www.quantisnow.com/insight/sec-form-3-ivor-royston-claimed-ownership-of-559198-units-430448) - 2021-02-24 21:34 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-429462) - 2021-02-24 11:06 UTC [SEC Form 10-K filed](https://www.quantisnow.com/insight/sec-form-10-k-filed-426261) - 2021-02-23 10:59 UTC [Analyst Upgrade] [Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target](https://www.quantisnow.com/insight/sunesis-pharmaceuticals-upgraded-by-oppenheimer-with-a-new-price-target-421140) - 2021-02-16 21:01 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-401584) - 2021-02-16 20:50 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-401337) - 2021-02-16 16:06 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-398961) - 2021-02-16 14:50 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-398318) - 2021-02-16 13:00 UTC [Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma](https://www.quantisnow.com/insight/viracta-therapeutics-announces-notice-of-allowance-for-us-patent-application-396723) - 2021-02-16 11:24 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-395763) - 2021-02-12 21:32 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-391670) - 2021-02-12 21:30 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-391544) - 2021-02-11 22:14 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-385841) - 2021-02-11 21:05 UTC [Conference Announcement] [Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences](https://www.quantisnow.com/insight/viracta-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-384732) - 2021-01-15 05:15 UTC [SEC Form EFFECT filed](https://www.quantisnow.com/insight/sec-form-effect-filed-287357) - 2021-01-14 22:11 UTC [SEC Form 424B3 filed](https://www.quantisnow.com/insight/sec-form-424b3-filed-286533) - 2021-01-13 02:54 UTC [SEC Form S-4/A filed](https://www.quantisnow.com/insight/sec-form-s-4a-filed-279910) - 2021-01-07 23:01 UTC [SEC Form 3: S Parvinder Hyare claimed ownership of 960 units of Common Stock](https://www.quantisnow.com/insight/sec-form-3-s-parvinder-hyare-claimed-ownership-of-960-267399) - 2021-01-07 13:39 UTC [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-265238) - 2021-01-04 17:35 UTC [SEC Form SC 13G filed](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-250447) - 2020-12-22 11:28 UTC [SEC Form 8 filed](https://www.quantisnow.com/insight/sec-form-8-filed-232096) - 2020-12-22 11:26 UTC [SEC Form 4 filed](https://www.quantisnow.com/insight/sec-form-4-filed-232091) - 2020-12-22 11:24 UTC [SEC Form S filed](https://www.quantisnow.com/insight/sec-form-s-filed-232085) - 2020-12-07 13:30 UTC [Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA](https://www.quantisnow.com/insight/viracta-therapeutics-announces-presentation-of-updated-phase-2-data-at-200600) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SNSS - Earnings history: https://www.quantisnow.com/earnings/SNSS - Dividend history: https://www.quantisnow.com/dividends/SNSS - Insider transactions: https://www.quantisnow.com/insiders/SNSS - Options chain: https://www.quantisnow.com/options/SNSS - SEC 8-K filings only: https://www.quantisnow.com/company/SNSS/8-k - RSS and alerts for SNSS: https://www.quantisnow.com/docs/rss-feeds.md